Norstella retweeted
Vaccine development is entering a more selective phase. In @WSJ, Daniel Chancellor, VP Thought Leadership at @NorstellaCo, explains how post‑pandemic realities are shaping investor appetite and vaccine pipelines.
Read Daniel’s take here: vist.ly/4xjza
Every morning, something shifts in pharma and biotech that industry insiders need to grasp before the day runs away from them.
@CapsulNews is how they do that. Six minutes. Free for a limited period.
Follow: teapaw.org/CapsulNews
👉 Sign up here: capsul.news/
144
In bleeding disorders, the drugs work. The fight now is over how rarely patients have to think about treatment. @CapsulNews, published by Norstella's News & Insights division, breaks down this week's ISTH Congress readouts in hemophilia A and von Willebrand disease.
Hemophilia A & von Willebrand disease both had major ISTH readouts this week. The drugs work. The fight is now over how rarely patients have to think about treatment.
Today's @CapsulNews breaks it down - free.
Read today's entire edition here capsul.news/trial-tuesday-in…
122
Bayer's plan for winning in oncology: don't outbid rivals for promising drugs, just get there before the bidding starts. Capsul News (@CapsulNews), published by Norstella's News & Insights division, breaks down the incubator, the AI deals, and the Asia strategy behind it.
Replying to @Bayer
@Bayer's BD strategy in one line: be in the room before there's a room. Its Co.Lab incubator, AI deals with Iambic and Cradle, and 3 Asian sites are all the same bet - relationships are cheaper than auctions.
Full read in today's Long View
Read it here capsul.news/the-long-v/
1
144
RNA drugs were built for rare diseases. Now, 30+ are being tested for common ones like high cholesterol and hypertension. @CapsulNews, published by Norstella's News & Insights division, shares its take on the shift and the Lp(a) trials that could make or break the class.
RNA drugs were built for rare disease. Now 30+ are in trials for hypertension, Lp(a), and dyslipidemia.
Three Lp(a) outcomes trials read out this year - a win or loss reshapes the entire class.
Full breakdown in @CapsulNews's Therapeutic Thursdays
capsul.news/therapeutic-thur…
1
87
Health Canada is rebranding a dreaded moment in a trial as a courtesy call before E6(R3) hits. Capsul News, published by Norstella's News & Insights division, on what it means for sponsors below. 👇
Health Canada is offering sponsors a no-consequences clinical trial inspection before its E6(R3) deadline.
No rating. No report. No CAPA.
But proportionate doesn't mean minimal - and regulators already know the difference.
76
Norstella retweeted
What does the current investment landscape really look like for emerging biotechs? BIO's Chad Wessel and @danpharma, VP of Thought Leadership at @NorstellaCo, broke down the data on venture capital, M&A, licensing trends, and what early stage companies need to know to navigate today's market. #BIO2026
Read more in Bio.News: bio.news/bio-convention/bio-…
Earlier this month, Josh Murphy appeared on the Real-World Wednesdays Podcast to discuss the evolution of RWD and Norstella's role in finding more patients, faster. Take a listen: vist.ly/4z5ns.
1
49
Vaccine development is entering a more selective phase. In @WSJ, Daniel Chancellor, VP Thought Leadership at @NorstellaCo, explains how post‑pandemic realities are shaping investor appetite and vaccine pipelines.
Read Daniel’s take here: vist.ly/4xjza
Why has vaccine investment fallen faster than other therapy areas? In @WSJ, Daniel Chancellor, VP Thought Leadership at @NorstellaCo, explains how shifting investor priorities are reshaping vaccines.
Read Daniel’s take here: vist.ly/4wsf6
38
Advancing vaccine platforms are raising the bar for what counts as innovation. @NorstellaCo’s Daniel Chancellor shared with @WSJ why this makes new vaccine investments harder to justify.
Read Daniel’s take here: vist.ly/4wmxm
22
What’s keeping vaccine investors in the game? @NorstellaCo’s Daniel Chancellor told @WSJ that advances in vaccine technologies are “raising the bar for new entrants even higher.”
Check out the article here (subscription may be required): vist.ly/4w9t5
19
In rare diseases, traditional real-world data sources often fall short, leaving teams across research, medical, and commercial functions with blind spots. However, with NorstellaLinQ, rare diseases are not unreachable. Find out how. vist.ly/4w8cy
1
17
Norstella and Moffitt Cancer Center presented new research at the 2026 ASCO Genitourinary Cancers Symposium. vist.ly/4vme7
The poster, “The Association of Androgen Deprivation Therapy on Time to Dementia: A Large Competing Risk Analysis,” explores the risk of dementia in ADT patients and highlights new insights into treatment impact and patient outcomes.
Check out the research here. asco.org/abstracts-presentat…
1
36
Join Norstella at MAPS Americas to discuss how Medical Affairs teams can leverage real-world data to advance evidence strategy and scientific engagement. vist.ly/4vgxa
Our experts will share approaches for identifying care gaps, detecting early clinical signals and emerging phenotypes, supporting new indication exploration, and quantifying unmet need to guide RWE investment.
We’ll also discuss how these insights can enable field medical teams and inform abstracts, publications, and congress planning.
23
vist.ly/4vfiu | The evolving pharma dynamic between the US and China is capturing a lot of attention, but where does that leave Europe? Norstella's @danpharma took the time to pen an editorial for @pharmaphorummedia, drawing on our data and the opening keynote he chaired during BIO-Europe. pharmaphorum.com/market-acce…
34
Attending MAPS Americas? Connect with Norstella’s RWD experts to explore how real-world evidence can help Medical Affairs teams identify where scientific engagement is most needed. vist.ly/4usti
From care gap insights and rare patient identification to HCP-specific practice patterns and field medical enablement, we help teams translate data into actionable insights that support MSL engagement, evidence planning, and publication strategy.
Schedule a meeting to learn more.
43
vist.ly/4uj7j | Within weeks of launch, oral semaglutide uptake surged, but three-quarters of initiators hadn’t used a GLP-1 injectable before. That suggests oral GLP-1s may be expanding the treated population — not just reshuffling it. Allison Perry and Ilan Behm break down what NorstellaLinQ data found, and what manufacturers need to know.
37
vist.ly/4ufaw | Although each rare disease affects a relatively small number of people, there are between 6,000 and 10,000 rare conditions worldwide. Many are extraordinarily uncommon—some with only a handful of documented cases.
In this article, Andrew Warmington explains why the term “rare” can be misleading. Collectively, these conditions affect an estimated 300 million people globally, and about 5% of the world’s population will experience a rare disease at some point.
This broader view highlights the scale of need and the importance of continued research, awareness, and support.
21
vist.ly/4uaqz | Oral semaglutide saw rapid uptake within weeks of launch. But here’s the real insight: ~75% of early initiators hadn’t previously used a GLP-1 injection — despite being clinically eligible.
This wasn’t just switching.
It was latent demand being activated.
In the oral GLP-1 market, understanding who is starting therapy matters more than prescription counts alone. Allison Perry and Ilan Behm explain why.
1
38











